Publication:
Aberrant Expression of c-Met and HGF/c-Met Pathway Provides Survival Advantage in B-Chronic Lymphocytic Leukemia

dc.contributor.authorsEksioglu-Demiralp, Emel; Akdeniz, Tuba; Bayik, Mahmut
dc.date.accessioned2022-03-14T10:06:05Z
dc.date.accessioned2026-01-10T18:36:00Z
dc.date.available2022-03-14T10:06:05Z
dc.date.issued2011-01
dc.description.abstractBackground: B-chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of CD5(+) B lymphocytes. Decreased VLA-4 (Cd49d/CD29) and CD11a expression and defective adhesion in B-CLL have been previously shown, although there was no substantial data about its importance in immunobiology of B-CLL. The hepatocyte growth factor (HGF) receptor, c-met, plays a role in adhesion by acting on VLA-4. c-met and VLA-4 share crucial signaling molecules in cell survival. In this study, relationship between expressions of c-met and CD49d, CD11a, and additional common signaling molecules in B-CLL was investigated. Methods: White blood cells from 24 patients with CLL were studied by flow cytometry and/or western blotting prior to and after culturing with recombinant HGF. HGF level from sera was measured with a bead-based flow cytometric assay. Results: c-met alpha and c-met beta were expressed on B-CLL cells, while no expression was observed on normal donor CD19+ cells. This increase was inversely correlated with decreased expression of adhesion molecules. Serum level of HGF in B-CLL was found to be increased. In vitro experiments showed that HGF supported survival in B-CLL cells supporting the possible function of HGF/c-met pathway in B-CLL. Furthermore, expressions of critical signaling molecules shared by both VLA-4 and HGF/c-met systems including Bcl-XL, Akt, PI3K, and phospho-bad(136) following HGF stimulations of B-CLL cells have been found to be increased. Conclusion: Increased expression of c-met and HGF may bypass the importance of expression of critical adhesion molecules and support survival of B-CLL cells. c-met, being one of the surface tyrosine kinases, may serve as a target for future therapies in B-CLL meriting more attention. (C) 2010 International Clinical Cytometry Society
dc.identifier.doi10.1002/cyto.b.20553
dc.identifier.issn1552-4949
dc.identifier.pubmed20809501
dc.identifier.urihttps://hdl.handle.net/11424/244042
dc.identifier.wosWOS:000285981000001
dc.language.isoeng
dc.publisherWILEY-LISS
dc.relation.ispartofCYTOMETRY PART B-CLINICAL CYTOMETRY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectB-CLL
dc.subjectCD49d
dc.subjectc-met alpha
dc.subjectc-met beta
dc.subjectHGF
dc.subjectflow cytometry
dc.subjectbead-based cytometric assays
dc.subjectHEPATOCYTE GROWTH-FACTOR
dc.subjectMARROW STROMAL CELLS
dc.subjectSIGNAL-TRANSDUCTION
dc.subjectADHESION MOLECULES
dc.subjectANTIGEN RECEPTOR
dc.subjectPROGENITOR CELLS
dc.subjectACTIVATION
dc.subjectAPOPTOSIS
dc.subjectKINASE
dc.subjectVLA-4
dc.titleAberrant Expression of c-Met and HGF/c-Met Pathway Provides Survival Advantage in B-Chronic Lymphocytic Leukemia
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage7
oaire.citation.issue1
oaire.citation.startPage1
oaire.citation.titleCYTOMETRY PART B-CLINICAL CYTOMETRY
oaire.citation.volume80B

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
539.35 KB
Format:
Adobe Portable Document Format